WO2009058399A1

WO2009058399A1 - A new class of therapeutics that enhance small molecule diffusion

Info

Publication number: WO2009058399A1
Application number: PCT/US2008/012440
Authority: WO
Inventors: John L. Gainer
Original assignee: Diffusion Pharmaceuticals Llc
Priority date: 2007-10-31
Filing date: 2008-10-31
Publication date: 2009-05-07
Also published as: US8206751B2; US20090110746A1; US20130018014A1; CA2703946A1; KR20100083820A; JP2016026156A; CN101878040A; MX2010004803A; JP2011502125A; AU2008319225B2; EP2214714A4; EA201070544A1; EP2214714A1; BRPI0818119A2; ZA201003475B; IL205417A0; AU2008319225A1

Abstract

The subject application relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.

Description

A New Class of Therapeutics that Enhance Small Molecule Diffusion

This application claims priority from U.S. Provisional Patent Application No. 61/001,095, the entire contents of which are hereby incorporated by reference.

The subject application relates to novel compositions and their use in enhancing small molecule diffusion, and in the case of oxygen in vivo, oxygenation of tissues. This class of compounds is called diffusion enhancing compounds.

Background of the Invention

The terms 'kosmotrope' (order-maker) and 'chaotrope' (disorder-maker) originally denoted solutes that stabilized, or destabilized respectively, proteins and membranes. More recently, the terms have also been used to refer to compounds having the apparently correlating property of increasing, or decreasing respectively, the structuring (ordering) of water. Some compounds (e.g. urea) can act as kosmotropes and chaotropes, depending on the concentration of the compound in a hydrogen bonding environment such as water.

Both the extent and strength of hydrogen bonding may be changed by a kosmotrope. The effect of a kosmotrope on increasing the amount of hydrogen bonding in an aqueous solution is especially important. By effecting such a change in the hydrogen bonding in the solution, a kosmotrope shifts the local equilibrium shown below to the left (and chaotropes shift it to the right)

less dense water ^more dense water.

In other words, the addition of a kosmotrope to an aqueous system results in a decrease in density of that system. So, by increasing the structure, or order, of the water through the formation of more hydrogen bonds, kosmotropes cause the solution density to decrease. Kosmotropes are currently used to stabilize proteins, such as enzymes. It is also said that they affect the phase behavior of lipids. Some well-known kosmotropes are proline, glycine betaine and trehalose. See also Moelbert, S. et al., Biophysical Chemistry, 1 12, 45-57, 2OO4.The website: http://www.lsbu.ac.uk is a good reference for kosmotropes and chaotropes.

Gainer et al. Chem. Eng. Commun. 15: 323-329, 1982, showed that crocetin caused an increase in the specific volume of water.

Gainer et al. Ind. Engr. Chem. Research, 33: 2341-2344, 1994 showed that the diffusivity through a solution was proportional to the change in the specific volume.

Carotenoids are a class of hydrocarbons consisting of isoprenoid units. The backbone of the molecule consists of conjugated carbon-carbon double and single bonds, and can also have pendant groups. Carotenoids such as crocetin and trans sodium crocetinate (TSC) are known to increase the diffusivity of oxygen in water.

US Patent 6,060,51 1 relates to trans sodium crocetinate (TSC) and its uses. The patent covers various uses of TSC such as improving oxygen diffusivity and treatment of hemorrhagic shock.

US Patent application Ser. No. 10/647,132 relates to synthesis methods for making bipolar trans carotenoid salts (BTC) and methods of using them.

US Patent application Ser. No. 11/361,054 relates to improved BTC synthesis methods and novel uses of the BTC.

US Patent application Ser. No. 60/907,718 relates to the use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease.

Trans sodium crocetinate (TSC) increases the amount of hydrogen bonding when dissolved in water, Stennett et al. J. Phys. Chem. B, 110: 18078-18080, 2006. In Okonkwo et al, Neurosci Lett. 352(2):97-100, 2003, the authors measured brain oxygen levels in rats. As expected, having the rats breathe 100 % oxygen caused the brain oxygen level to increase. An unexpected result was that administering TSC to rats breathing 100% oxygen further increased the brain oxygen level. The combination of 100% oxygen and TSC gave a greater effect than either one alone. In animals suffering from an oxygen deficiency, TSC can be used as a treatment, Giassi, L. J. et al. J. Trauma, 51 : 932-938, 2001, and Gainer et al. PuIm. Pharmacol. &Therapeutics, 18: 213-216 (2005).

Summary of the Invention

The subject invention relates to pharmaceutical compositions comprising a diffusion enhancing compound such as a kosmotrope, and a pharmaceutically acceptable carrier.

The invention also relates to a variety of methods of treatment including methods of enhancing the diffusion of oxygen, treating hemorrhagic shock, or treating a hypoxic condition in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

The invention also relates to a method of treating cancer comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound as an adjunct to radiation therapy and/or chemotherapy.

The invention also relates to treating diseases where organs do not get enough oxygen such as Wegener's granulomatosis with a diffusion enhancing compound including bipolar trans carotenoids, and to treating arthritis with a diffusion enhancing compound including a bipolar trans carotenoid other than crocetin.

Detailed Description of the Invention

The subject invention relates to novel compositions and their use in treating a variety of disorders where enhanced tissue oxygenation is beneficial. As used herein, "diffusion enhancing compound" is a compound that causes an increase in the rate of movement of a small molecule through an aqueous system. Diffusion enhancing compounds increase the specific volume of the aqueous system by increasing water structure by affecting the extent and strength of hydrogen bonding among water molecules.

The movement of oxygen through plasma is thought to be a limiting, or controlling, step in the uptake and release of oxygen from red blood cells (Holland, RAB, Shibata, H., Scheid, P, Piiper, J: Respiration Physiology, 59: 71-91, 1988; Huxley, VH, Kutchai, H: J. Physiology, 316: 75-83, 1981; Yamaguchi, K, Nguyen-Phu, P. Scheid, P, Piiper, J: J. Applied Physiology, 58: 1215-1224, 1985). Thus, in order to increase the rate at which oxygen gets to the body tissues, it is important to enhance its movement through the plasma.

Oxygen can move through the plasma, especially in the smaller blood vessels (the capillaries), via molecular diffusion which depends on the oxygen concentration gradient as well as a factor called the diffusion coefficient (or diffusivity). This diffusion coefficient reflects the basic resistance of the plasma to the movement of other molecules like oxygen, through it. If it were possible to decrease the resistance of the plasma, oxygen would move faster through it and this would be reflected as an increased diffusivity. One way to do this is to decrease the plasma density with a diffusion enhancing compound. Usually when one adds a chemical compound to a given volume of plasma, the density (mass/volume) increases. Thus, in order to decrease the density of plasma when adding another substance, the compound added must also increase the volume of the liquid as well as the mass of the solution. This will result in a decrease in the density (mass/volume). Specific volume is inversely related to the density. Increasing the specific volume (volume/mass) of the blood plasma implies, altering the "structure" of its water molecules.

Compounds that decrease the water density and increase the specific volume are kosmotropes. Kosmotropes are said to shift the equilibrium shown below to the left while compounds called chaotropes shift it to the right:

less dense water ^ more dense water

Thus, kosmotropes are diffusion enhancing compounds. How they act to decrease water density has been suggested to be through increasing the water structure through increased hydrogen bonding. Plasma is mostly water and water molecules are bound to each other by hydrogen bonds.

The terms 'kosmotrope' (order-maker) and 'chaotrope' (disorder-maker) also denote solutes that stabilized, or destabilized respectively, proteins and membranes. Another term used to classify compounds and ions which stabilize proteins in cells is osmolyte. A number of chemical compounds are included on both the lists of osmolytes and the lists of kosmotropes. Osmolytes are frequently concentrated inside tissue cells.

As used herein "diffusion enhancing kosmotrope" denotes kosmotropes having the capability to increase the structuring (ordering) of water, resulting in a decreased density and an increased diffusivity of oxygen through an aqueous solution like plasma.

Both the extent and strength of hydrogen bonding can be changed by a kosmotrope. Some compounds (e.g. urea) can act as both a kosmotrope and a chaotrope, depending on the concentration of the compound in a hydrogen bonding environment such as water. Some of the better-known kosmotropes are proline, glycine betaine and trehalose.

As shown in the Examples below, it can be seen that kosmotropes increase the diffusivity of solutes (such as glucose and oxygen) through aqueous solutions. They do this because kosmotropes cause increased hydrogen bonding among the water molecules, which, in turn, leads to a less dense liquid structure.

Also included in diffusion enhancing compounds are the bipolar trans carotenoid compounds. Carotenoids are not found on standard lists of kosmotropes; however, it has been found that a carotenoid, trans sodium crocetinate (TSC), can enhance water structure (Laidig, K. E., Gainer, J. L., Daggett, Valerie: Journal of the American Chemical Society, 120: 9394-9395, 1998) as well as cause increased hydrogen-bonding in water (Stennett, A. K., Dempsey, G. L., Gainer, J. L.: J. of Physical Chem. B, 110: 18078-18080, 2006). Trans sodium crocetinate is also known to increase the diffusivity of both oxygen and glucose (Stennett, A. K., Dempsey, G. L., Gainer, J. L.: J. of Physical Chem. B, 110: 18078-18080, 2006).

Thus, diffusion enhancing compounds can cause increased water structure and decreased density, resulting in increased diffusivity through aqueous solutions such as blood plasma. These properties enable these compounds to perform as therapeutics to increase tissue oxygenation.

Other diffusion enhancing compounds increase the diffusion through aqueous solutions through the same mechanism, i.e., by decreasing the density and altering the water structure by increasing the hydrogen bonding among the water molecules. There are accepted methods of determining whether or not a compound increases the hydrogen bonding of water (Stennett et al., J. Phys. Chem. B., 110, 18078-18080, 2006).

Diffusion enhancing compounds will increase tissue oxygenation in a mammal. If the mammal is oxygen-deficient, or hypoxic, then no enriched oxygen gases are needed to observe the effect of a diffusion enhancing compound. If the mammal is not suffering from a form of hypoxia, then enriched oxygen gases plus a diffusion enhancing compound will deliver more oxygen to the tissue than the enriched oxygen gases can do alone.

Compounds and Compositions of the Invention

Included in the Compounds of the Invention are the following diffusion enhancing compounds:

Bipolar Trans Carotenoids such as trans sodium crocetinate (TSC). See also the compounds disclosed in US Ser. No. 10/647,132 and US Ser. No. 11/361,054 hereby incorporated by reference in their entirety

Kosmotropes are effective in enhancing diffusion. As used herein, the term "kosmotrope" means a chemical compound that results in increased water structure by increasing hydrogen bonding among water molecules. Another characteristic of the kosmotropes of the invention are non toxic at therapeutically effective concentrations. Kosmotropes of the invention include:

Trimethylamine TV-oxide

Proline

Ectoine

Trehalose, maltose and other disaccharides that can increase hydrogen bonding

Glycine betaine

3-Dimethylsulfoniopropionate

Urea at certain concentrations [it can be the opposite (a chaotrope) at other concentrations]

Maltose Glycerol 2- J-

Small or multiply-charged ions, with high charge density (e.g. SCM , HPO 4 , Mg , C -a 2 ⁺ , Li ⁺ , Na ⁺ , OH -, F^", Cl^") t-butanol Fructose

DMSO (dimethylsulfoxide) at certain concentrations (it is like urea in that it is a chaotrope at other concentrations) and other related compounds which also function as kosmotropes.

Other compounds that enhance the diffusion of oxygen in an aqueous system are also useful. In addition to the compounds above, the skilled person can use assays as described herein and known to those skilled in the art, to identify diffusion enhancing compounds that increase the specific volume of an aqueous system by increasing water structure by affecting the extent and strength of hydrogen bonding among water molecules.

The compounds of the subject invention are all manufactured to be pharmaceutical grade. Although the compounds of the invention can be administered alone, they can also be administered as part of a pharmaceutical composition. Such formulations can include pharmaceutically acceptable carriers known to those skilled in the art as well as other therapeutic agents-see below. Advantageously, the formulation does not include a compound that inhibits the ability of the compounds of the invention to improve diffusivity.

The compounds can be formulated using agents known to increase solubility such as cyclodextrins, polyethylene glycol, glycols, etc. Other agents can be added to buffer the diffusion enhancing compounds. Other agents can be added to affect the osmolality, as well as compounding agents needed for oral formulations.

The formulations can conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and can be prepared and administered by methods known in the art of pharmacy. The formulation can be for immediate, or slow or controlled release of the diffusion enhancing compound. See, for example, the controlled release formulation of WO 99/15150 hereby incorporated by reference in its entirety.

Formulations of the present invention suitable for oral administration can be presented as discrete units such as pills, capsules, cachets or tablets, as powder or granules, or as a solution, suspension or emulsion. Formulations suitable for oral administration further include lozenges, pastilles, and inhalation mists administered in a suitable base or liquid carrier. Formulations for topical administration to the skin can be presented as ointments, creams, gels, and pastes comprising the active agent and a pharmaceutically acceptable carrier or in a transdermal patch.

Formulations suitable for nasal administration wherein the carrier is a solid include powders of a particular size that can be administered by rapid inhalation through the nasal passage. Suitable formulations wherein the carrier is a liquid can be administered, for example as a nasal spray or drops.

Formulations suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, compounds to improve solubility of the active agent, solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions which can include suspending agents and thickening agents.

The formulations can be presented in unit or multi-dose containers, for example sealed ampules and vials, and can be lyophilized or crystallized, requiring only the addition of the sterile liquid carrier such as water for injection immediately prior to use. Injection solutions and suspensions can be prepared from sterile powders, granules and tablets. Therapeutic Uses and Modes of Administration of the Compounds and Compositions of the Invention

The compounds and compositions of the invention have therapeutic uses in treating mammals having conditions of reduced oxygen usage.

The uses include those disclosed in commonly owned US patent 6,060,511, US Patent application Ser. No. 10/647,132, US Patent application Ser. No. 11/361,054, and US Patent application Ser. No. 60/907,718 each of which is hereby incorporated by reference in its entirety. The compounds are useful in the treatment of:

hemorrhagic shock, respiratory disease, asthma, emphysema, ALI, ARDS, COPD

cardiovascular disease, atherosclerosis, myocardial infarction, hypertension, ischemia, stroke, traumatic brain injury,

Alzheimer's disease,

arthritis,

anemia, (anemia of prematurity, Fanconi anemia, hymolytic anemia, microcytic anemia, a normochromic anemia, a macrocytic anemia, hereditary spherocytosis, sickle-cell anemia, warm autoimmune hemolytic anemia, cold agglutinin hemolytic anemia),

chronic renal failure, hypertension, cerebral edema, papillomas, spinal chord injuries

cancer (advantageously as an adjunct to i) radiation therapy including external beam radiation, gamma knife, brachytherapy, tomotherapy, and proton beam, including fractionated, 3D conformal radiotherapy, intracavitary radiation, and intensity modulated radiotherapy (IMRT), and/or ii) chemotherapy including temozolimide), diabetes, diabetic retinopathy,

peripheral vascular disease/claudication , embolism, blood clot, spinal stenosis/neurogenic claudication,

diseases where organs do not get enough oxygen such as Wegener's granulomatosis

performance when respiration/exertion is increased/stressed,

The compounds and compositions of the invention are also useful as a pretreatment or for treating mammals at risk for the above-noted diseases/conditions.

As evidenced by the Examples below, diffusion enhancing compounds increase tissue oxygenation and thus can be used to treat oxygen deficient diseases. The concentration/dose of the diffusion enhancing compound selected will be that concentration that causes increased hydrogen bonding among the water molecules of the blood plasma and results in increased diffusivity. This concentration can be determined by those skilled in the art.

Typically the diffusion enhancing compounds are administered by any suitable route including oral, nasal or inhalation, topical, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, transdermal and intraosseus), vaginal or rectal. The preferred route of administration will depend on the circumstances. An inhalation route is advantageous for treatment in emergency situations, where it is necessary for the diffusion enhancing compound to enter the bloodstream very quickly. The formulations thus include those suitable for administration through such routes (liquid or powder to be nebulized). It will be appreciated that the preferred route may vary, for example, with the condition and age of the patient. Appropriate dosages of the compounds and compositions of the invention as well as the mode of administration, will depend on the metabolism of the given compound, and the severity of the condition being treated. For a dose to be "therapeutically effective", it must have the desired effect, i.e. increase diffusivity. The minimum dosage needed for treatment for any of these diffusion enhancing compounds is that at which the diffusivity increases. The therapeutically effective dosage of the compounds of the invention will depend upon the condition treated, the severity of the condition, the stage and individual characteristics of each mammalian patient addressed, and the clearance of the diffusion enhancing effect.

In one embodiment, more than one diffusion enhancing compound is administered. In another embodiment, the diffusion enhancing compound is administered along with oxygen. Alternatively, hemoglobins or fluorocarbons and a diffusion enhancing compound can be given together. In a still further embodiment, the diffusion enhancing compound is administered along with an erythropoiesis stimulating compound such as erythropoietin.

In another embodiment, diffusion enhancing compound can be used to increase the diffusivity of other physiologically important molecules other than oxygen such as glucose, CO2, or NO.

Non-therapeutic Uses

Lastly, the compounds of the invention can be used to enhance diffusivity in aqueous systems outside the body, for example in fermentations and other cultures of microorganisms.

The following examples are illustrative, but not limiting of the compounds, compositions and methods of the present invention. Other suitable modifications, and adaptations of a variety of conditions and parameters normally encountered which are obvious to those skilled in the art are within the spirit and scope of the invention.

EXAMPLES

EXAMPLE 1

Increasing glucose and oxygen transport in vitro

The effect of each of 3 kosmotropes (proline, betaine and trehalose) on the rate of diffusion though a water solution has been tested in the following manner. c

Glucose Diffusion

The diffusion of glucose through aqueous solutions of the above-mentioned kosmotropes was measured using a microinterferometric method, Secor, R. M., AIChE Journal, 11. 452-456, 1965.

In this method, a wedge is formed by two microscope slides that have a partial coating of a metal such as aluminum on the inner sides of the wedge. The wedge is placed on a microscope stage and illuminated from below using some source of monochromatic light, such as a helium-neon laser. As the light passes through the wedge, the partial coating of aluminum allows some light to be transmitted, while some is reflected. This creates constructive and destructive lines known as interference fringes. The interference fringes can then be magnified by a microscope and recorded with a camera.

Molecules of glucose will diffuse along a concentration gradient of glucose. Since the refractive index of the solution is related to the concentration of the glucose, the fringes at a given point will change with time. From the time behavior in the fringe pattern, one can calculate the diffusion coefficient, or diffusivity, at each time increment. These values become constant at longer times, and that final value is taken to be the diffusion coefficient of glucose in that particular aqueous solution.

Solutions of three kosmotropes (proline, betaine and trehalose) in water were made, so that the solutions contained about 10 μM of each of the kosmotropes. Using the trehalose solution as an example, the diffusivity of glucose through each of these solutions was then measured in the following way.

The trehalose solution was divided into two parts. A strip of one part of the trehalose solution was placed on one of the coated slides. A wedge was formed by placing a cover slip on one end of one of the coated slides and then resting the other coated slide on top. The wedge was placed on a microscope stage and a light source was turned on. A camera recorded the resulting fringe pattern.

Glucose was added to the second portion of the trehalose solution so that the glucose concentration in that solution was 0.9 molar. A drop of this trehalose-glucose solution was then introduced into the wedge, using a syringe, in such a manner so that the drop touched the strip of trehalose solution that was already in the wedge. Care was taken to assure that the two solutions did not mix when they touched, and, if they did, the solution was discarded and the procedure started over.

A stopwatch was turned on at the time that the two solutions touched. Pictures of the fringe patterns were taken at various times over the next several minutes. Using these pictures, it is possible to calculate the diffusivity of glucose through the trehalose solution. That calculation method is given in Secor, R. M., AIChE Journal, 11: 452-456, 1965.

The measurements were done at a temperature of 25° C, and the apparatus was calibrated by measuring the diffusivity of glucose in plain distilled water, with the value obtained being (6.9 + 0.3) X 10 ^"6 cm²/s. This closely corresponds to the CRC Handbook value of 6.7 X lO ^"6 cm²/s CRC Handbook of Chemistry and Physics, edited by D. R. Lide, CRC Press, Boca Raton, FL, 1998, p.6-181.

The values of the diffusivity of glucose through the solutions containing the trehalose and the other kosmotropes were greater than the value of glucose through plain water. The percentage increases in the diffusivities of glucose due to each kosmotrope is shown in the following graph:

Common Kosmotropes

% Increase in Diffusivity

Betaine Proline Trehalose Compound

The preceding diffusion measurement was also done for TSC in water, and it was found that TSC caused an increase in the diffusivity of glucose through water at TSC concentrations from 1 μmole/liter to around 200 μmole/liter of around 30% , Stennett, A. et al. J. Phys. Chem. B, 110: 18078-18080, 2006.

Oxygen Diffusion

In addition, the diffusivity of oxygen through TSC-water solutions was also measured over the same TSC concentration range as for the glucose diffusion studies. Since oxygen is a gas, the diffusivity had to be measured differently, in an apparatus commonly used for such purposes, Goldstick, T. K., PhD Dissertation, University of California, Berkeley, CA, 1966, pps. 13-28. In that experiment, the movement of oxygen across a liquid layer is determined by measuring the concentration at the opposite boundary of the liquid layer over time using an electrode, and the diffusivity calculated. All measurements were done at 25 ⁰C, and it was found that TSC increases the diffusion of both oxygen and glucose through water by a similar percentage, Stennett, A. K. et al. J. Phys. Chem. B, 110: 18078-18080, 2006.

Based on these data, it can be seen that kosmotropes increase the difrusivity of solutes (such as glucose and oxygen) through aqueous solutions.

EXAMPLE 2

Increasing oxygen transport in vivo

Diffusion enhancing compounds such as kosmotropes increase the oxygen transport in vivo. In the subject experiment, the oxygen diffusing through the skin of a normal, non-diseased rat was measured using a transcutaneous oxygen monitor (TCOM). In the subject study, the rats breathed air and then were switched to breathing 100% oxygen at a time equal to zero. Also at time zero, the rats were injected (intravenously in the femoral vein) with either saline (control), trehalose, glycine betaine, or TSC.

The following three graphs show that trehalose, TSC, or glycine betaine result in an increased oxygen transport across the skin. All of these compounds increase the TCOM readings, as shown below by the average increases (+ standard error). Thus, TSC, betaine and trehalose increase oxygen transport in vivo.

Change in TCOM with 100% Oxygen

Minutes after 100%Oxygen + Injection

Change in TCOM with 100% Oxygen mg/kg,

Minutes after 100% oxygen + injection It will be readily apparent to those skilled in the art that numerous modifications and additions can be made to both the present compounds and compositions, and the related methods without=departing from the invention disclosed.

Claims

What is claimed is:

1. A pharmaceutical composition comprising a diffusion enhancing compound and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising a unit dose of a diffusion enhancing compound and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition as in claim 1 wherein the diffusion enhancing compound is selected from the group consisting of trimethylamine N-oxide, proline, ectoine, trehalose and other disaccharides which increase hydrogen bonding, glycine betaine, 3-dimethylsulfoniopropionate, urea, maltose, glycerol, a small or multiply- charged ion with high charge density, t-butanol, and DMSO (dimethylsulfoxide).

4. A pharmaceutical composition as in claim 1 wherein the diffusion enhancing compound is selected from the group consisting of trehalose, glycine betaine, and proline.

5. A pharmaceutical composition as in claim 3 wherein the small or multiply-

2- charged ion with high charge density is selected from the group consisting of SO-=! , HPOr, Mg^{2 +}, Ca^{2 +} , Li ⁺ , Na ⁺ , OH -, F, and CY .

6. A pharmaceutical composition as claim 1 wherein the composition is an aqueous based solution.

7. A pharmaceutical composition as in claim 1 wherein the pharmaceutically acceptable carrier is selected from the group consisting of cyclodextrins, PEG and glycols.

8. A method of enhancing the diffusion of oxygen in a mammal comprising administering a diffusion enhancing compound other than a bipolar trans carotenoid in an amount sufficient to increase the diffusion of oxygen in blood plasma.

9. A method of treating hemorrhagic shock in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

10. A method of treating a hypoxic condition in a mammal comprising administering to said mammal a diffusion enhancing compound other than a bipolar trans carotenoid in an amount sufficient to increase tissue oxygenation.

11. A method of treating respiratory disease, asthma, emphysema, ALI, ARDS, COPD in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

12. A method of treating cardiovascular disease, myocardial infarction, hypertension, ischemia or stroke, in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

13. A method of treating traumatic brain injury or Alzheimer's disease in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

14. A method of treating anemia in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

15. A method of treating chronic renal failure in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

16. A method of treating cancer in a mammal comprising administering before during or after radiation therapy or chemotherapy to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

17. A method of treating hypertension or myocardial infarction in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

18. A method of treating diabetes, diabetic retinopathy, peripheral vascular disease/claudication, or spinal stenosis/neurogenic claudication in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than a bipolar trans carotenoid.

19. A method as in claim 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the diffusion enhancing compound is selected from the group consisting of trimethylamine iV-oxide, proline, ectoine, maltose, trehalose and other disaccharides which cause increased hydrogen bonding, glycine betaine, 3-dimethylsulfoniopropionate, urea, glycerol, a small or multiply-charged ion with high charge density, t-butanol, and DMSO (dimethylsulfoxide).

20. A method as in claim 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the diffusion enhancing compound is selected from the group consisting of trehalose, glycine betaine, and proline.

21. A method as in claim 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein said administration is selected from the group consisting of nasal, parenteral, transdermal, intramuscular injection and oral delivery.

22. A method of treating Wegener's granulomatosis in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound.

23. A method of treating cancer in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound as an adjunct to radiation therapy and/or chemotherapy.

24. A method of treating arthritis in a mammal comprising administering to said mammal a therapeutically effective amount of a diffusion enhancing compound other than crocetin.

25. A method as in claim 22, 23 or 24, wherein the diffusion enhancing compound is a bipolar trans carotenoid.

26. A method as in claim 22, 23 or 24, wherein the diffusion enhancing compound is TSC.